The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
We have entered an era where it is now possible to sequence an individual's genetic blueprint. In the case of cancer this can be used to determine the genetic damage that has occurred in cancer cells. This fellowship seeks to carry out large scale sequencing of cancer patient and map out the genetic damage that is common to get a handle on what drives the disease. It will also investigate how personalized mutation detection might improve cancer treatment selection for individual patients.
Defining Genomic Mechanisms Associated With Treatment Response, Drug Resistance And Early Blast Crisis In Chronic Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$631,370.00
Summary
Chronic myeloid leukaemia is a fatal disease if untreated. Most patients now survive with new drugs, but some still rapidly die. I aim to understand these differences by investigating the genetic makeup of patients at diagnosis. Some may have gene mutations that prevent drugs from working effectively. Mutations will be detected using technology that can search more than 30,000 genes at the same time. This work could lead to improved survival for more patients by finding new targets for therapy.
I am a biochemical geneticist working on inherited disorders that affect the musculoskeletal system. My major focus is determining the molecular basis of muscular dystrophies and bone and cartilage disorders.
Breast And Ovarian Cancer: Beyond Genome Wide Association Studies
Funder
National Health and Medical Research Council
Funding Amount
$863,910.00
Summary
My research is focused on using genetic approaches to understand the basis of cancer, particularly breast and ovarian cancer. Although many risk factors have been identified for these cancers, they do not lend themselves to primary prevention, except for high risk individuals who opt for prophylactic surgery, and so there is an urgent need to understand the aetiology of these cancers in order to develop better risk prediction algorithms and risk reduction medications.
Chronic Disease Epidemiology In Different Populations: Risk Factors, Detection And Prevention
Funder
National Health and Medical Research Council
Funding Amount
$621,458.00
Summary
To investigate causes, detection and prevention of diabetes, cardiovascular disease, and kidney disease in Aboriginal and international populations, I will maintain a long-term cohort with a 20-year follow-up in Aboriginal people and to analyse several large repeated cross-sectional data collected over 25 years in China. For the next 5 years, I will continue to to provide critical epidemiological evidence for the development of health policies and clinical guidelines related to chronic diseases ....To investigate causes, detection and prevention of diabetes, cardiovascular disease, and kidney disease in Aboriginal and international populations, I will maintain a long-term cohort with a 20-year follow-up in Aboriginal people and to analyse several large repeated cross-sectional data collected over 25 years in China. For the next 5 years, I will continue to to provide critical epidemiological evidence for the development of health policies and clinical guidelines related to chronic diseases in different populations.Read moreRead less
Genetics And Genomics Of Breast And Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$714,745.00
Summary
Our knowledge of the number and nature of the genes involved in breast and ovarian cancer is limited. To rapidly define the critical breast and ovarian cancer-causing genes my laboratory uses an integrative genomics approach whereby information from several genome-wide platforms are combined. A key initiative that will underpin much of our work is Lifepool, which is a unique cohort of 100,000 Victorian women attending BreastScreen that will support a range of research into breast cancer.
Strategies For Enhancing The Treatment Of Colon Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$590,785.00
Summary
Colorectal cancer is the third leading cause of cancer related death in Australia. Strategies to improve outcomes for these patients are urgently needed. This NHMRC SRF Fellowship will seek to identify new molecules in cancer cells which can be targeted to treat this disease, and to discover genes which can be used to improve patient response to treatment.
Research Fellowship – Genetic Epidemiology Studies Of Hormonal Cancers To Inform Improved Healthcare
Funder
National Health and Medical Research Council
Funding Amount
$772,209.00
Summary
This study aims to identify genetic factors that influence the development of endometrial and other cancers, and to develop statistical and laboratory methods that can better determine if variation in a known cancer gene is disease-causing. The results will be used to identify and prioritise individuals at greatest risk of cancer for the most appropriate clinical management. Discovery of novel cancer genes will improve our understanding of disease development to develop future therapies.
Molecular Mechanisms And Functional Consequences - Understanding Endocrine Tumorigenesis
Funder
National Health and Medical Research Council
Funding Amount
$124,530.00
Summary
A/Prof Marsh is focused on discovering the causes of both inherited and non-inherited endocrine tumours, translating this knowledge into medical practice for the improved diagnosis of cancer and using this knowledge to highlight new therapeutic options for people who have cancer. She is internationally recognised for her work on a protein linked to the development of parathyroid cancer and is working towards improving our understanding of women’s cancers.
This application will increase the impact of cancer immunotherapy on disease prevention and treatment, by developing new targets and novel combination immunotherapies. Outcomes will include an improved understanding of the immune reaction with cancer and more effective strategies to prevent cancer spread and safely target and eradicate a larger proportion of established and advanced malignant disease.